PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML

PATHWAY-DIRECTED THERAPY APPROACH IN PEDIATRIC MDS AND AML

Bibliographic Details
Main Author:	Barbara De Moerloose
Format:	Article
Language:	English
Published:	Elsevier 2023-12-01
Series:	EJC Paediatric Oncology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772610X23000600

Similar Items

Inherited predisposition to MDS/AML
by: Ana Rio Machin, et al.
Published: (2018-06-01)

p53 biology and reactivation for improved therapy in MDS and AML
by: Joanna E. Zawacka
Published: (2024-03-01)

VENETOCLAX-BASED THERAPIES IN PEDIATRIC ADVANCED MDS AND RELAPSED/REFRACTORY AML: A MULTICENTER RETROSPECTIVE ANALYSIS
by: Riccardo Masetti, et al.
Published: (2023-12-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
by: Christoforos K. Vaxevanis, et al.
Published: (2023-12-01)

Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy
by: Guancui Yang, et al.
Published: (2022-10-01)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
by: Hoyle, C, et al.
Published: (1989)

Gene expression profiling in MDS and AML: potential and future avenues.
by: Theilgaard-Mönch, K, et al.
Published: (2011)

Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients
by: Jensen O, et al.
Published: (2022-02-01)

Telomere length is an independent prognostic marker in MDS but not in de novo AML
by: Williams, J, et al.
Published: (2017)

Rewriting the rules for care of MDS and AML patients in the time of COVID-19
by: Azra Raza, et al.
Published: (2020-01-01)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
by: V. Van Oorschot, et al.
Published: (2022-06-01)

P739: THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML
by: A. G. Lema Fernandez, et al.
Published: (2022-06-01)

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
by: Hongjiao Li, et al.
Published: (2023-09-01)

Short Dysfunctional Telomere is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients
by: Nadia El Menshawy, et al.
Published: (2020-07-01)

Polyclonal evolution of Fanconi anemia to MDS and AML revealed at single cell resolution
by: Lixian Chang, et al.
Published: (2022-09-01)

The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
by: Ana Rio-Machin, et al.
Published: (2020-02-01)

Interpretation of the 5th edition of the WHO classification of haematolymphoid tumours on MDS and AML
by: YE Xiangjun, LU Xingguo
Published: (2023-10-01)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
by: T. Ueda, et al.
Published: (2024-01-01)

Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML
by: Daniel Heudobler, et al.
Published: (2018-11-01)

P577: 20% BLAST CRITERIA FOR DIAGNOSING AML/MDS: IS IT TIME TO MOVE BEYOND?
by: V. Sheth, et al.
Published: (2022-06-01)

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?
by: Anson Snow, et al.
Published: (2022-07-01)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
by: Sandra Huber, et al.
Published: (2023-08-01)

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials
by: Tahsin Anwar, et al.
Published: (2023-12-01)

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML
by: Anne Sophie Kubasch, et al.
Published: (2018-05-01)

Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk of AML/MDS
by: Peter Vandenberghe, et al.
Published: (2011-06-01)

Targeted Therapies for Pediatric AML: Gaps and Perspective
by: Annalisa Lonetti, et al.
Published: (2019-11-01)

Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7
by: Hiroyoshi Kunimoto, et al.
Published: (2020-10-01)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.
by: Barreyro, L, et al.
Published: (2012)

A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
by: A. Shastri, et al.
Published: (2024-01-01)

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs
by: Hongjiao Li, et al.
Published: (2023-11-01)

Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
by: Zuzana Tothova, et al.
Published: (2021-02-01)

P471: ERYTHROID/MEGAKARYOCYTIC DIFFERENTIATION BIAS IN BONE MARROW OF AML/MDS PATIENTS AFTER DECITABINE TREATMENT
by: F. Tiso, et al.
Published: (2022-06-01)

Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
by: Patrice Chevallier, et al.
Published: (2016-11-01)

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
by: Jacobien R. Hilberink, et al.
Published: (2023-06-01)

Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins
by: Marcus Bauer, et al.
Published: (2020-09-01)

MicroRNAs distinguish cytogenetic subgroups in pediatric AML and contribute to complex regulatory networks in AML-relevant pathways.
by: Svenja Daschkey, et al.
Published: (2013-01-01)

Identification of a Complex Karyotype Signature with Clinical Implications in AML and MDS-EB Using Gene Expression Profiling
by: Cheonghwa Lee, et al.
Published: (2023-11-01)

Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML
by: Marcus Bauer, et al.
Published: (2024-12-01)

PB1773: AML AND MDS WITH RARA OVEREXPRESSION: MOLECULAR AND CLINICAL FEATURES OF PATIENTS ENROLLED IN A PHASE 2 TRIAL EVALUATING TAMIBAROTENE-BASED THERAPY
by: Stéphane de Botton, et al.
Published: (2023-08-01)

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
by: Jeroen Janssen, et al.
Published: (2021-02-01)